VirusArchives
Five years of SARS-CoV-2 evolution: variants, mechanisms, and public health challenges
Virus 1 min.
Since its emergence in 2019, SARS-CoV-2 has shown remarkable evolutionary plasticity, profoundly shaping the course of the COVID-19 pandemic. This review summarizes key evolutionary milestones from 2019 to 2025, highlighting mechanisms such as point mutations, positive selection, recombination, and evolution...
Is dose adjustment of dolutegravir necessary in Chinese adults living with HIV across different body weight levels? A population pharmacokinetics analysis
Virus 1 min.
Dolutegravir (DTG) is an integrase strand transfer inhibitor indicated for human immunodeficiency virus (HIV) infection. Although intrinsic factors show no ethnic-specific impact on DTG pharmacokinetics, extrinsic factors may modulate its pharmacokinetic profile. This study developed a population pharmacokinetic...
Decline of HIV infection: legacy of tenofovir (A. Holý) and rilpivirine (P. Janssen)
Virus 1 min.
Among the wide variety of antivirals that have been developed for the treatment of human immunodeficiency virus (HIV) infections and acquired immunodeficiency syndrome (AIDS), two stand out: tenofovir and rilpivirine. The names unmistakenly associated with the discovery of these two compounds, are Antonín...
The potential roles of IgG glycosylation in the development of non-communicable comorbidities in people with HIV
Virus 1 min.
The introduction of effective antiretroviral therapy (ART) has transformed Human Immunodeficiency Virus (HIV) infection from a once-fatal diagnosis into a manageable chronic condition, with life expectancy in people with HIV approaching that of the general population. However, this extended lifespan...
